1Feldmann M, Brennan F M. The Role of Cytokine in Rheumatoid Arthritis[ J ]. Ann Rev Immunol, 1996,14:397- 440.
2Maini R N, Breedveld F C, Kalden J R, et al. Sustained Improvement over Two Years in Physical Function, Structural Damage, and Signs and Symptoms among Patients with Rheumatoid Arthritis Treated with Infliximab and Methotrexate[ J ].Arthritis Rheum, 2004, 50:1051-1065.
3Giles J T, Bathon J M. Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases[ J ]. J Intensive Care Med,2004,19:320-333.
4Askling J Fored C M, Brandt L, Baecklund E, et al. Risk and Casecharacteristics of Tuberculosis in Rheumatoid Arthritis Associated with Tumor Necrosis Factor Antagonists in Sweden[ J ]. Arthritis Rheum, 2005, 52:1986-1992.
5Maini R N, Breedveld F C, Kalden J R, et al. Therapeutic Efficacy of Muhipleintravenous Infusions of Anti-tumornecrosis Factor Alpha Monoclonal Antibody Combined with Low-dose Weekly Methotrexate in Rheumatoid Arthritis[ J ]. Arthritis Rheum, 1998, 41:1552-1563.
6K L Hyrich, K D Watson, A J Silman, et al. Predictors of Response to Anti-TNF- Therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register[J]. Rheumatology, 2006, 45:1558- 1565.
7Van Der Heijde D, Ktareskog L, Rodriguez-Valverde V, et al. Anti-tumor Necrosis Factor Trial In Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis[ J ]. N Engl J Med, 2000, 343:1594-1602.
8Rahman M U, Strusberg I, Geusens P, et al. Doubleblinded Infliximab Dose Escalation in Patients with Rheumatoid Arthritis[ J ]. Ann Rheum Dis, 2007, 66(9):1233-1238.
9Westhovens R, Yocum D, Han J, et al. The Safety of Infliximab, Combined with Background Treatments, among Patients with Rheumatoid Arthritis and Various Comorbidities: A Large, Randomized, Placebo-Controlled Trial [ J ]. Arthritis Rheum, 2006,54(4): 1075-1086.
10RAJAKULENDRAN S, DEIGHTON C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNF alpha drug [J]. Curr Drug Saf, 2006, 1 (3) : 259-264.
4Schroeder K W,Tremaine W J,Ilstrup D M.Coated oral5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis[J].N Engl J Med,1987,317(26):1625-1629.
